Paraquat Herbicide Litigation (Parkinson's Disease)

Paraquat dichloride is one of the most acutely toxic herbicides in the world. So poisonous that a single sip can be fatal to humans, it is classified as a restricted-use pesticide by the EPA and can only be applied by certified, licensed applicators. Despite its extreme toxicity, paraquat remained one of the most widely used herbicides in U.S. agriculture for decades, applied on millions of acres of crops including soybeans, corn, cotton, and fruit orchards.

A growing body of epidemiological and toxicological research linked occupational paraquat exposure to a significantly elevated risk of developing Parkinson's disease — the second most common neurodegenerative disorder, affecting nearly one million Americans. Paraquat is banned in over 60 countries, including all European Union member states, China, Brazil, and Switzerland (where manufacturer Syngenta is headquartered), due to health concerns. The United States remained one of the few developed nations that permitted its use.

Internal company documents obtained during litigation suggested that Syngenta (the primary manufacturer, formerly part of ICI/Zeneca) was aware of the Parkinson's disease risk as early as the 1960s based on its own animal studies, but actively worked to suppress and undermine independent research linking paraquat to neurodegeneration.

The litigation drew heavily on the structural similarity between paraquat and MPP+ (1-methyl-4-phenylpyridinium), a known neurotoxin that is the gold standard for inducing Parkinson's-like symptoms in laboratory research. This structural parallel provided a compelling mechanistic explanation for paraquat's neurotoxic effects.

The epidemiological evidence linking paraquat to Parkinson's disease was substantial and formed the scientific foundation of the litigation. A 2011 study in the American Journal of Epidemiology, using data from the Agricultural Health Study — one of the largest prospective studies of pesticide exposure and health — found that paraquat use was associated with a 2.5-fold increased risk of Parkinson's disease (OR 2.5, 95% CI 1.4–4.7). Meta-analyses found risk increases ranging from 150% to over 600% with chronic exposure.

The mechanistic evidence was equally compelling. Paraquat's chemical structure is nearly identical to MPP+ (1-methyl-4-phenylpyridinium), the active metabolite of MPTP — a synthetic compound that selectively destroys dopamine-producing neurons in the substantia nigra, the brain region critically affected in Parkinson's disease. This structural similarity is not coincidental: both compounds generate reactive oxygen species (free radicals) that overwhelm cellular antioxidant defenses, leading to oxidative stress and neuronal death.

Laboratory studies demonstrated that paraquat crosses the blood-brain barrier, accumulates in dopaminergic neurons, and induces the same pathological cascade — oxidative stress, mitochondrial dysfunction, alpha-synuclein aggregation — observed in Parkinson's disease.

Paraquat's ban in over 60 countries reflected the international scientific consensus on its unacceptable neurotoxic risk. The European Union revoked its authorization in 2007, citing unacceptable risks to agricultural workers' health.

This litigation has been resolved through a confidential settlement. Individuals who believe they may have been affected by paraquat exposure should consult a licensed attorney to understand whether any legal options remain available.

The original litigation involved agricultural workers, licensed pesticide applicators, farm laborers, mixer-loaders, crop dusters, and others with occupational exposure to paraquat who were subsequently diagnosed with Parkinson's disease or parkinsonism. Farm family members exposed through spray drift were also represented.

This eligibility information is general and informational only. Consult a licensed attorney.

A confidential settlement framework was reached in 2025 (first announced in April 2025 and formalized later that year) to resolve claims in MDL No. 3004 before Chief Judge Nancy J. Rosenstengel in the Southern District of Illinois. The total amount has not been disclosed.

The settlement is still being implemented. As of September 1, 2026, 6,666 cases remained pending in the MDL, out of 8,488 filed. The court has required plaintiffs who opted out of the settlement to provide information about their diagnosis and exposure history and to meet with a special master.

Before the settlement, the litigation suffered a major setback for plaintiffs: in April 2024 the court excluded plaintiffs' general causation expert and dismissed the first four bellwether cases. No paraquat bellwether case in the MDL has gone to a jury verdict.

Individuals who were not part of the MDL should consult an attorney to understand whether any legal options remain.

Syngenta and Chevron maintained throughout the litigation that paraquat does not cause Parkinson's disease when used according to label directions. The companies argued that the epidemiological evidence was insufficient to establish causation and that the animal studies showing neurological effects used unrealistically high doses. Syngenta emphasized that paraquat remains registered for use in the United States by the EPA.

The companies' decision to settle — despite these stated defenses — reflects the significant litigation risk posed by damaging internal documents and strong plaintiffs' science.

A confidential settlement framework was reached in 2025 to resolve the bulk of claims in MDL No. 3004. The amount has not been publicly disclosed, and the settlement was still being implemented in 2026.

No bellwether case in the MDL reached a jury verdict. In April 2024 the court excluded plaintiffs' general causation expert and dismissed the first four bellwether cases before trial.

Past settlement amounts are not a guarantee of future results.